NICHOLAS IN JV WITH BOOTS

Article Abstract:

Boots Healthcare International (BHI) of UK has entered into a joint venture with Nicholas Piramal India Ltd (NPIL). The joint venture company, Boots Piramal Healthcare Ltd (BPHL), will develop and market consumer healthcare products in India. NPIL will hold 49 percent stake in BPHL while BHI will hold 51 percent stake. BPHL will have an equity of Rs5 crore. It will market three of BHI's brands - Strepsils, Icy and Sweetex and NPIL's skin care brands - Lobate and Melalite. BHPL will be headquartered in Mumbai. (ag)

Comment:

Forms Boots Piramal Healthcare in JV with Boots Healthcare Intnl to develop and market consumer healthcare products in India

United Kingdom, Boots Healthcare International, Nicholas Piramal India Ltd., Boots Piramal Healthcare Ltd.

---

BAYER, ZYDUS GROUP IN PHARMA MARKETING JV

Article Abstract:

The Zydus group of Ahmedabad is floating a marketing joint venture with Bayer AG of Germany. The joint venture company, Bayer Zydus will commence operations from January 1, 1999. The joint venture will be set up at an investment of about Rs20 crore. Bayer Zydus will be selling the existing products of Bayer in India and also some select brands of Zydus. Bayer (India) will be transferring its marketing staff to the new company. The new company will aim at a market share of 2.2 percent in the next 3-5 years. (ag)

Comment:

Forms Bayer Zydus w/ Zydus Group to sell the existing products of Bayer in India & also some select brands of Zydus, India

Chemicals & Allied Products, Chemical Manufacturing, Chemicals, Bayer AG, Bayer Zydus

---

ZYDUS IN JV WITH GERMAN MAJOR BYK GULDEN

Article Abstract:

The Zydus group has entered into a 50:50 joint venture Byk Gulden of Germany to manufacture, market and distribute pharmaceutical intermediates and formulations. The venture will also involve itself in research and development activities. The joint venture, to be called Zydus-Byk, will be a 100 percent export oriented unit. It will be set up at a cost of Rs20 crore. Byk Gulden will source key intermediates to produce bulk drug Pantoprazole from Zydus-Byk. (khr)

Comment:

Enters joint venture w/ Zydus Group to form Zydus-Byk to produce, market & distribute pharmaceutical intermediates & formulation

Zydus-Byk, Byk Gulden

Similar abstracts:

• Abstracts: FRENCH TAKE SHOTS AT BASMATI POT INDIA OPPOSES USE OF BASMATI TRADEMARK BY FRENCH Co IN DEFENCE OF BASMATI
• Abstracts: BATA INDIA LTD BATA GAINS GROUND, TURNOVER ON THE RISE
• Abstracts: DANISH CO, IFU TO SET UP Rs25-M JV IN INDIA THAKRAL GROUP SETS UP RAFFLES IN INDIA ROOT CONSULTING SETS UP INDIAN ARM IN CHENNAI
• Abstracts: WEB INFOTECH, IBM SIGN PACT FOR ERP MEDINFO-ONLINE, INFOTECH IN PACT IMPACT SOLUTIONS LAUNCHES ONLINE SHOPPING SITE
• Abstracts: ICICI TO FUND ELECTROLUX JV ACQUISITION OF VOLTAS UNIT. VOLTAS HIVING OFF AGRO UNIT TO RALLIS; POSTS Rs7.1 Cr LOSS

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.